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ABSTRACT
Cardiovascular disease (CVD) and cancer represent the two main causes of death in industrial-
ised countries. Both share common risk factors (diabetes, obesity, hypertension, diet, smoking,
etc.). The associated timing of CVD and cancer onset is thus largely influenced by modifiable
risk factors. Advances in cancer treatment have extended the lives of patients with cancer, but
for some at the cost of adverse cardiovascular events. The rapidly growing number of patients
surviving cancer, often in the setting of advanced age, new or pre-existing CV disease and risk
factors, the management of these patients has become the concern of experts in cardio-oncol-
ogy. The goal of cardio-oncology is to provide optimal care for patients with cancer and/or at
risk of cardiovascular disease. To date, no specific cardio-oncology teaching programme is avail-
able in Belgium. The present paper reports the results of the Belgian Society of Cardiology (BSC)
survey on cardio-oncology. The vast majority of respondents (154/159, 97%) are in favour of
organising courses or educational meetings on cardio-oncology. A dedicated cardio-oncology
clinic was present in only 40% of the hospitals that participated in the survey. Compared to the
data collected by the European Society of Cardiology, the number of respondents considering
themselves as experts in the management of left ventricular dysfunction or atrial fibrillation
complicating cancer treatment was much lower in Belgium (11% vs. 30%).
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Heart and cancer: common risk factors
Worldwide, the total number of people alive within
5 years of being diagnosed with cancer is estimated at
43.8 million ("200,000 in Belgium) [1,2]. To date,
about 423 million people suffer from cardiovascular
diseases, themselves associated with 17.9 million
deaths [1]. In Belgium, heart disease and cancer com-
bine to account for 31% and 23% of deaths in women
and 27% and 29% of deaths in men [2,3]. Although
commonly thought of as two separate disease entities,
cardiovascular disease (CVD) and cancer possess vari-
ous similarities and possible interactions, including a
number of similar risk factors (age, obesity, diabetes
mellitus), suggesting a shared biology [4,5]. The associ-
ated timing of CVD and cancer onset is thus largely
influenced by modifiable risk factors. The incidence of
both cancer and CVD increases with advancing age
with 3=4 of new cancer diagnoses occurring in individu-
als #55 years in developed countries (>50% in
patients >70 years in Belgium) [6]. Cigarette smoking
greatly impacts cardiovascular incidence and mortality,
contributing to all stages of atherosclerosis through
various mechanisms [7]. Tobacco usage, particularly
smoking ("23% of Belgian inhabitants), is also a pre-
ventable and heavily weighted risk factor for multiple
cancer types. Smoking is responsible for 30% of all
cancer-related deaths [8]. Hypertension ("25% of
Belgian inhabitants) is a well-established CVD risk fac-
tor [9]. Hypertension is a major health problem world-
wide, as it affects approximately 3 in 10 adults over
age 20, leading to high morbidity and mortality.
Hypertension is associated with several specific cancer
types with a particularly strong association with renal
cell carcinoma (1.6-fold increase) [10]. Obesity ("20%
are overweight in Belgium) represents a significant risk
factor for cancer; up to 20% of all cancer may be
weight-related [11]. The carcinogenic effects of obesity
on sex can differ, and this is most substantial for colon
cancer (55% increased risk of colorectal cancer in men
than in women) [12]. The potential protective effect of
elevated oestrogen levels commonly observed in
obesity can, however, be counteracted by an
increased risk of breast and endometrial cancer
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[13,14]. The deleterious effects of diabetes mellitus
("6.4% of Belgian inhabitants) on the macrovascula-
ture render it a coronary heart disease risk equivalent
[15]. Numerous studies link diabetes mellitus to cancer
risk (as much as a 2.5-fold increased risk for certain
cancers, especially in women) and its progression
(colorectal, breast, endometrial, liver, pancreatic, and
bladder cancers) [16]. The role of dietary composition
in cancer risk ranges from known carcinogens in food
sources to dietary components impacting obesity,
hypertension, hyperlipidaemia, and chronic inflamma-
tory patterns that mediate cancer risk [17]. Serum lipid
Table 1. Questions asked and responses received from 159 cardiologists.
Questions responses
Your age?
$ Under 30 $ 3%
$ 30–44 $ 40%
$ 45–60 $ 43%
$ Over 60 $ 14%
Your gender?
$ Female $ 30%
$ Male $ 69%
$ Prefer not to answer $ 1%
Where are you working?
$ Academic university hospital $ 47%
$ Community public hospital $ 40%
$ Cardiology practice $ 7%
$ Other, please specify $ 6%
What is the size of your hospital?
$ <300 beds $ 4%
$ 300–600 $ 33%
$ >600 $ 64%
Do you have at your hospital a dedicated cardio oncology clinic?
$ Yes $ 40%
$ No $ 60%
How many patients with a possible CV complication of cancer treatment did you see in the last 12 months?
$ None $ 3%
$ 1–5 $ 29%
$ 5–20 $ 42%
$ >20 $ 26%
In your professional environment where are ambulatory cancer patients with cardiovascular health problems reviewed?
$ General cardiology clinic $ 54%
$ A part time single specialist Cardio-Oncology Service $ 16%
$ Structured Cardio-Oncology Service with one or two dedicated specialists inside a community hospital $ 11%
$ Cardio-Oncology Centre inside a large tertiary hospital $ 10%
$ Cardio-Oncology Centre inside a large Oncologic specialist hospital $ 7%
$ Other – please describe $ 3%
How do you judge your knowledge and skills about management of patients with left ventricular dysfunction complicating cancer treatment?
$ Scarce $ 7%
$ Acceptable $ 33%
$ Fair $ 49%
$ Expert $ 11%
How do you judge your knowledge and skills about management and anticoagulation of patients with atrial fibrillation complicating cancer treatment?
$ Scarce $ 5%
$ Acceptable $ 38%
$ Fair $ 45%
$ Expert $ 12%
In your specific clinical environment do you receive referrals from GPs or other specialists to evaluate a patient with cardiac problems who has received
previous cancer therapy?
$ Never $ 7%
$ Rarely (1–5 times/year) $ 39%
$ Moderately (5–20/year) $ 26%
$ Frequently (>20/year) $ 29%
Are you regularly reviewing patients with a known history of cancer treatment for CV diseases?
$ Never $ 1%
$ Rarely $ 34%
$ Commonly $ 65%
Did you read and apply suggestions of the 2016 ESC Position Paper on cancer treatments and cardiovascular toxicities?
$ No $ 17%
$ I don’t know this position paper $ 16%
$ I read it but I don’t apply it in my practice $ 11%
$ I read it and I always apply its suggestions in my practice $ 56%
Should the BSC host educational courses or meetings on specific aspects of Cardio-Oncology?
$ No – I don’t need it $ 3%
$ Maybe $ 28%
$ Yes $ 69%
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levels have a well-known association with coronary
artery disease [18]. Hyperlipidaemia as a risk factor for
cancer remains inconclusive, although it appears more
convincing for breast cancer and less conclusive for
some other cancers [19]. High alcohol levels are associ-
ated with increased CVD and risk of oropharyngeal,
laryngeal, oesophageal, liver, colorectal, and pre- and
post-menopausal breast cancers [20]. Inactivity and
low-grade chronic inflammation also increased the risk
of CVD and cancer [21,22]. In Belgium, physical activity
is graded insufficient in one in three adults [3].
Keeping all this in mind, priority should be thus given
to targeting common risk factors and addressing
comorbidities that cause these two highly morbid dis-
eases, as this would not only reduce the burden of
the disease, but would be potentially cost-effective.
Cardio-oncology service
Advances in cancer treatment have extended the lives
of patients with cancer, but for some at the cost of
adverse cardiovascular events [23,24]. Increasing age,
underlying heart disease, and other comorbidities are
contributing factors [14]. Cardiovascular complications
from cancer therapy have become a leading cause of
morbidity and mortality in cancer survivors. Compared
with relatives, cancer survivors are 10 times more
likely to develop coronary artery disease, heart failure,
or a cerebrovascular event [25]. Among survivors with
any type of cancer diagnosed before the age of
55 years, the risk of cardiovascular death is more than
ten-fold greater than in the general population
[26,27]. The risk of death from CVD is several times (2
to 6-fold) that of the general population in the first
year of diagnosis; this risk increases as survivors are
followed for ten years or more. Cancer has thus to be
considered an independent risk factor for CVD [28]. As
a result, the medical community is increasingly con-
cerned about the cardiovascular health of cancer
patients. Screening for cardiovascular risk factors and
anti-cancer-related complications by dedicated care
providers has thus been advocated [29]. The origins of
cardio-oncology date back late in the 1960s, when car-
diac dysfunction resulting from anthracyclines was first
recognised as an important side effect. The field since
then has arisen in few centres, and in the past years
has rapidly evolved and become more a formal sub-
specialty with smaller units emerging within major
centres [30]. Cardio-oncology is a burgeoning cardi-
ology discipline, clinically focussing on the cardiovas-
cular care of patients with active cancer, patients
treated with cancer therapies associated with CVD risk,
and prevention and treatment of CVD in cancer survi-
vors. The ultimate goal is to provide optimal care for
patients with cancer and/or at risk of CVD. Cardio-
oncology services are conceived as an alliance of dedi-
cated professionals, to provide multidisciplinary speci-
alised evaluation and consistent, continuous,
coordinated and cost-effective care, during the cancer
process. The early recognition of the cardiac side
effects of anti-cancer agents and radiation therapy,
balanced with the knowledge of the natural history of
the malignancy and the benefits of oncologic treat-
ments, is known to offer the greatest opportunity for
long-term disease-free survival [31–33]. The establish-
ment of a training and education programme in car-
dio-oncology has thus become a priority for the
cardiology and oncology community (oncologists, hae-
matologists, radiotherapists) [34].
Belgian Society Cardiology survey on
cardio-oncology
Cardio-oncology practice requires a complex organisa-
tion that may differ substantially among hospitals and
communities [29,30]. Little is known about the current
knowledge, service structure and the activity of cardi-
ologists looking after cancer patients in Belgium.
Consequently, the Belgian Society of Cardiology (BSC)
decided in 2019 to extend the survey carried out by
the European Society of Cardiology (ESC) Cardio-
Oncology Council, in which very few Belgian centres
had participated. The survey was sent out to 606
members of the BSC. A total of 159 responses were
collected, representing 26.2% of the population who
received the questionnaire, which was significantly
higher than that of the European Council (Table 1).
The majority of respondents were between 30 and
60 years old (83%). Males were more represented than
females (69% vs. 31%). Most of the participants
worked in an academic university hospital (47%) or in
a community public hospital (40%). A dedicated car-
dio-oncology clinic was present in only 40% of the
hospitals. In response to how many patients with pos-
sible cardiovascular complication of cancer treatment
were seen in the previous 12months, 74% of the
respondents had seen between 1 and 20 patients
while 26% had seen over 20 patients. About 54% of
the respondents worked in general cardiology clinic,
16% as a part time with only 3% working in dedicated
cardio-oncology centres in specialist cancer hospitals.
The majority of respondents rated their knowledge as
‘fair’ for their management of patients with common
cardiovascular conditions such as LV dysfunction
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(49%) and atrial fibrillation (45%) with around 11% rat-
ing themselves as experts in managing these patients
with a much smaller number rating their knowledge
as ‘poor’ (5–7%). Compared to the data collected by
the ESC, the number of experts (11% vs. 30%) is much
lower. About 29% of respondents stated to receive
more than 20 referrals annually from General
Practitioners. Respondents (65%) regularly reported
seeing cardiovascular patients with a known history of
cancer. Intriguingly, 44% of the respondents were not
aware or did not use the 2016 ESC position paper on
the management of cancer patients. When asked if
the BSC should host educational courses or meetings
on cardio-oncology, an overwhelming majority
responded positively (97%) with a strong yes in 69%
and a maybe in 28% (Figure 1). To date, no specific
cardio-oncology teaching programme has been organ-
ised in Belgium, whereas our neighbours (France, Italy,
Netherlands) have developed one a few years ago. It
should be noted that although this survey is the first
on the subject in Belgium, the data collected did not
allow a precise analysis of the frequency of the prac-
tice of cardio-oncology.
Conclusions
The management of cancer patients at risk or suffering
from cardiovascular complications remains complex
and requires a multidisciplinary approach. In the
absence of an education programme in this area,
Belgium remains behind its neighbours. Few Belgian
cardiologists consider themselves experts in the field
and few clinics dedicated to cardio-oncology are avail-
able. To fight CVD in cancer patients, the BSC has
launched a new Cardio-Oncology Council in order to
inform doctors on the prevention and management of
CVD related to cancer treatments and radiotherapy. A
specific research grant from the Belgian Heart
Foundation has also been created to promote research
in this area.
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